IntelliSep wins FDA clearance for sepsis diagnostic
- Cytovale’s IntelliSep sepsis test won FDA 510(k) clearance, giving U.S. emergency departments a cleared tool to flag sepsis risk from blood in minutes. - The test returns an IntelliSep Index in about 8 minutes, using white-blood-cell biophysical changes rather than pathogen detection, for adults with suspected infection. - That matters because sepsis has lacked a fast objective ED diagnostic, and clearance turns a novel host-response approach into a regulated product.
Sepsis diagnostics are tricky because the thing doctors need to catch fast is not a single germ. It is the body’s immune system spinning into a dangerous, organ-damaging response. That is why this FDA clearance matters. Cytovale’s IntelliSep is not another culture or biomarker panel — it is a regulated test built to help emergency departments sort out sepsis risk early, when minutes still matter. (accessdata.fda.gov) ### What actually got cleared? The FDA cleared IntelliSep through the 510(k) pathway under product code QUT and regulation 866.3215, with a decision date of December 20, 2022. The device classification itself is telling: “deformability cytometry for sepsis risk assessment.” In plain English, the agency did not just bless a generic lab workflow. It cleared a specific kind of sepsis-risk test built around how immune cells physically behave under stress. (accessdata.fda.gov) ### What does IntelliSep measure? IntelliSep looks at biophysical changes in white blood cells. Instead of asking, “Which pathogen is here?” it asks, “Does this patient’s immune system look like it is already tipping into sepsis?” That host-response angle is the whole pitch. Sepsis can come from many different infections, so a pathogen-agnostic test has an obvious advantage in the emergency department, where clinicians often have to act before cultures come back. (cytovale.com) ### Why is that useful in the ED? Because the ED problem is triage under uncertainty. A patient can arrive with fever, low blood pressure, confusion, or vague infection symptoms, and those signs overlap with a lot of other emergencies. IntelliSep is meant for adult patients who present with signs or suspicion of infection, and it gives a probability-style result fast enough to affect first decisions — treatment, monitoring intensity, and where the patient should go next. (cytovale.com) ### How fast is “fast” here? Cytovale says the test produces a result in about 8 minutes from tube to score. The output is a numerical IntelliSep Index from 0.1 to 10.0, grouped into three bands, with higher scores mapping to higher sepsis risk. That is a very ED-shaped product design. It is not trying to replace every downstream lab. It is trying to answer the first urgent question: how worried should we be right now? (cytovale.com) ### Why has sepsis been so hard to diagnose quickly? Because sepsis is a syndrome, not a single clean target. Heart attacks have troponin. Strokes have imaging patterns. Sepsis usually starts with a messier picture — infection, inflammation, and organ dysfunction evolving in real time. Cytovale’s own framing is blunt: unlike other time-sensitive emergencies, sepsis lacked a highly sensitive diagnostic test built for early detection. That gap is what IntelliSep is trying to close. (cytovale.com) ### Is this really “the first”? The useful version of that claim is narrower than the hype. IntelliSep appears to be the first FDA-cleared sepsis diagnostic in this new device class focused on deformability cytometry and emergency-department sepsis risk assessment. Cytovale has also been positioning it commercially as the first-of-its-kind sepsis diagnostic tool for EDs since launch. But the important part is not (cytovale.com)of host-response test as a formal regulated category. (accessdata.fda.gov) ### What changed after clearance? Clearance turned IntelliSep from an interesting technology story into something hospitals could actually buy and deploy inside normal workflows. Cytovale says the test fits standard ED and lab workflows, uses 100 microliters from a standard K2 EDTA blood tube, and can send results into the lab information system automatically. That sounds mundane, but it is the difference between a clever machine and a product clinicians might really use at scale. (cytovale.com) ### Bottom line? This is a diagnostics story, but really it is a workflow story. IntelliSep gives sepsis care something ED teams have wanted for years — a fast, objective read on risk before the full clinical picture settles. If hospitals adopt it broadly, the bigger shift will be less about “AI in medicine” branding and more about whether sepsis triage finally starts to look as immediate and standardized as other emergency diagnoses. (cytovale.com)
